Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial.

Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial.

There is high medical need for safe long-term immunosuppression monotherapy in kidney transplantation. Selective targeting of post-transplant alloantigen-(re)activated effector-T cells by anti-TNF antibodies after global T cell depletion may allow safe drug minimization, however, it is unsolved what...

Full description

Bibliographic Details
Main Authors: Ondrej Viklicky, Petra Hruba, Stefan Tomiuk, Sabrina Schmitz, Bernhard Gerstmayer, Birgit Sawitzki, Patrick Miqueu, Petra Mrazova, Irena Tycova, Eva Svobodova, Eva Honsova, Uwe Janssen, Hans-Dieter Volk, Petra Reinke
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5234822?pdf=render

Internet

http://europepmc.org/articles/PMC5234822?pdf=render

Similar Items